Study guide

14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction

CCI Registered Cardiac Sonographer RCS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: RCS Orientation and Clinical Context

1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context

2 Chapter 2: Orders, Safety, and Patient Preparation

2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare

3 Chapter 3: Reporting and 2-D TTE Foundations

3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA

4 Chapter 4: M-Mode and Doppler Acquisition

4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition

5 Chapter 5: Advanced Doppler and Contrast

5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts

6 Chapter 6: Stress Echocardiography

6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation

7 Chapter 7: TEE, Strain, and 3-D TEE

7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts

8 Chapter 8: 3-D TTE and the Aortic Valve

8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States

9 Chapter 9: Aortic Regurgitation and Mitral Structure

9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability

10 Chapter 10: Mitral and Tricuspid Valve Findings

10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment

11 Chapter 11: Right-Sided Valve Disease

11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment

12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves

12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch

13 Chapter 13: Endocarditis and Cardiac Chambers

13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function

14 Chapter 14: Cardiomyopathy Phenotypes and Diastology

14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls

15 Chapter 15: Systolic Function and Ischemia

15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications

16 Chapter 16: Pericardium and Great Vessels

16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation

17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition

17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues

18 Chapter 18: Devices, Strain, and Hemodynamics

18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts

19 Chapter 19: Infiltrative Disease and Physics Foundations

19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing

20 Chapter 20: Resolution and Doppler Optimization

20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain

21 Chapter 21: 2-D, 3-D, and Contrast Optimization

21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts

14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction

Key Takeaways Explain This Topic AI

Describe a dilated or hypertrophic phenotype and its hemodynamic consequences before proposing etiology; echocardiography alone rarely distinguishes every genetic, ischemic, inflammatory, toxic, metabolic, or loading cause.

For a dilated phenotype, quantify LV and RV size and function, regional motion, stroke volume, functional regurgitation, atrial remodeling, pressure estimates, and thrombus using reproducible chamber methods.

For suspected HCM, report hypertrophy distribution and maximal end-diastolic wall thickness while excluding foreshortening, tangential cuts, papillary muscle, and right-ventricular structures from the measurement.

Assess dynamic obstruction with 2-D anatomy, color and PW localization, correctly aligned CW at rest and with physiologic provocation, separating the LVOT envelope from MR and fixed obstruction.

Last updated: July 2026

Recognize the phenotype before naming the disease

CCI task D2 includes cardiomyopathy evaluation. A dilated cardiomyopathy phenotype has LV enlargement with systolic dysfunction that is not explained solely by abnormal loading. Measure biplane and, when feasible, 3-D end-diastolic and end-systolic volumes and EF from nonforeshortened views. Describe global versus regional dysfunction, GLS when technically valid, LV sphericity, wall thickness, stroke volume, spontaneous contrast or thrombus, and mechanical dyssynchrony. Use an ultrasound-enhancing agent when two or more contiguous segments or the apex are not adequately seen.

Extend the survey beyond the LV. Annular and papillary displacement can produce secondary MR; RV dysfunction and secondary TR may develop; atria enlarge as filling pressures rise. Record RV-focused dimensions and function, LA and RA volumes, IVC, pulmonary pressure, and other valve disease. A regional coronary pattern, scar, or aneurysm may favor ischemic injury, but advanced ischemic disease can look globally dilated. Myocarditis, genetic disease, tachycardia, alcohol or chemotherapy toxicity, pregnancy-associated disease, and endocrine or nutritional disorders can share the phenotype. Report what is observed and recommend interpreter-directed clinical, coronary, CMR, laboratory, or genetic correlation rather than assigning cause from LV shape alone.

  • Feature Dilated phenotype Hypertrophic phenotype
  • LV cavity Enlarged, often spherical Usually nondilated; may be small or normal

Wall pattern Normal or reduced relative thickness Focal, asymmetric, apical, midventricular, or concentric increase

Systolic function Commonly reduced EF and GLS EF often normal/hyperdynamic; GLS may be reduced regionally

Valve effect Tethering and annular dilation cause functional MR SAM and leaflet/papillary anatomy can cause posterior MR

Hemodynamics Low output and elevated filling pressure Dynamic LVOT or midventricular obstruction, diastolic dysfunction

Measure hypertrophy without manufacturing it

HCM is increased LV wall thickness not explained by another cardiac, systemic, syndromic, or metabolic cause. In an adult nondilated LV, maximal thickness at least 15 mm supports HCM; 13 mm can be diagnostic in an appropriate family or genetic context. These are clinical definitions, not permission to ignore hypertension, aortic stenosis, athlete remodeling, amyloidosis, Fabry disease, or other phenocopies. Describe the pattern and distribution rather than using “asymmetric septal hypertrophy” as a complete diagnosis.

Measure end-diastolic thickness in short-axis planes perpendicular to myocardium from base through apex, cross-checking long-axis views. Do not include RV trabeculation, moderator band, false tendon, papillary muscle, or epicardial fat. Tangential long-axis cuts overestimate septal thickness; apical foreshortening can hide apical HCM. Use contrast or CMR when borders, apex, maximal segment, apical aneurysm, or thrombus remain uncertain. Report LV mass, cavity volumes, EF, GLS when available, LA size, diastolic findings, RV involvement, and MR.

Connect SAM anatomy to dynamic obstruction

Inspect mitral leaflet length, coaptation position, papillary muscle number and displacement, chordal attachments, basal septal contour, and LVOT width. Systolic anterior motion (SAM) ranges from chordal motion to prolonged leaflet–septal contact. It can create a coaptation gap and often posteriorly directed MR. Central or anterior MR should prompt a search for intrinsic leaflet disease, although jet direction alone is not definitive. SAM is not specific to HCM; it also occurs with a small hyperdynamic LV, dehydration, sepsis, inotropes, vasodilation, Takotsubo syndrome, sigmoid septum, or after mitral or aortic intervention.

Use color to find systolic acceleration, then step a PW sample from the LV apex through the mid cavity and LVOT to localize its onset. Align CW through that site. Dynamic LVOT flow usually has a mid-to-late-systolic, concave or dagger-shaped envelope. Calculate peak instantaneous gradient with 4V² . A resting or provoked peak gradient at least 30 mmHg defines obstruction; 50 mmHg or more is a management-relevant threshold in symptomatic patients, not a stand-alone treatment decision. Record BP, heart rate, rhythm, position, and loading conditions with every gradient.

Avoid tracing MR as LVOT flow. MR frequently begins earlier, lasts longer, has a rounder contour, and reaches a higher velocity; color and PW localization plus a cleaner apical long-axis alignment help separate overlapping signals. A fixed subaortic membrane or valvar AS generally accelerates earlier and has structural evidence. Very late cavity-obliteration flow can arise away from the LVOT in any hyperdynamic ventricle. Serial stenoses invalidate casual use of the simplified Bernoulli and continuity equations.

If the resting gradient is below the protocol target, acquire Valsalva strain and standing or squat-to-stand maneuvers when safe and authorized. Reduced preload or afterload and increased contractility intensify dynamic obstruction. In symptomatic patients without a rest or bedside-provoked gradient of 50 mmHg, physiologic exercise echocardiography is recommended; dobutamine is not the routine provocation because it creates nonphysiologic gradients even in normal hearts. Preserve the medication and exercise protocol, acquire the gradient at peak upright exercise when possible or immediately after, and document symptoms and BP.

A complete report distinguishes phenotype from etiology and states maximal wall thickness and segment, SAM structure and contact, obstruction level, rest and provoked peak gradients, MR mechanism/severity, LV/RV and atrial response, apical aneurysm or thrombus, and limitations. Communicate severe obstruction with hypotension, suspected thrombus, new systolic dysfunction, or dangerous stress findings promptly.

Preserve serial comparability

Compare chamber volumes, EF, GLS method, wall thickness, valve severity, and gradients with prior studies using the same border and provocation conventions. Reverse remodeling after therapy and new dilation or systolic decline are clinically important, but an apparent change should first trigger review of loading conditions, rhythm, image plane, and measurement reproducibility.